Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (Clinical Pharmacokinetics, (2021), 10.1007/s40262-020-00971-2)

the Isoniazid Precision Dosing Group

doi:10.1007/s40262-021-01018-w

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (Clinical Pharmacokinetics, (2021), 10.1007/s40262-020-00971-2)

the Isoniazid Precision Dosing Group

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The original text states that all volume and clearance parameters were allometrically scaled based on total body weight and that allometric scaling based on fat-free mass was not considered as height is not always readily available in TDM practice. During model development, we decided that height can easily be collected and allometric scaling based on fatfree mass should be considered. Allometric scaling based on fat-free mass was significantly better than scaling based on total body weight and was included in the final model. All volume and clearance parameters listed in Table 2 are applicable for a patient with a fat-free mass of 45 kg. This error affects the text in three places:

Original language	English
Journal	Clinical Pharmacokinetics
DOIs	https://doi.org/10.1007/s40262-021-01018-w
Publication status	Published - 3 Apr 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s40262-021-01018-w

Cite this

@article{58dbd3ab6f3e4dae99db8abe9c22ca2c,

title = "Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (Clinical Pharmacokinetics, (2021), 10.1007/s40262-020-00971-2)",

abstract = "The original text states that all volume and clearance parameters were allometrically scaled based on total body weight and that allometric scaling based on fat-free mass was not considered as height is not always readily available in TDM practice. During model development, we decided that height can easily be collected and allometric scaling based on fatfree mass should be considered. Allometric scaling based on fat-free mass was significantly better than scaling based on total body weight and was included in the final model. All volume and clearance parameters listed in Table 2 are applicable for a patient with a fat-free mass of 45 kg. This error affects the text in three places:",

author = "{the Isoniazid Precision Dosing Group} and {van Beek}, {Stijn W.} and {ter Heine}, Rob and Alffenaar, {Jan Willem C.} and Cecile Magis-Escurra and Aarnoutse, {Rob E.} and Svensson, {Elin M.} and Boeree, {M. J.} and E. Burhan and R. Dawson and Diacon, {A. H.} and S. Gillespie and Mtabho, {C. M.} and Ntingiya, {N. E.} and N. Heinrich and W. Hoefsloot and M. Hoelscher and G. Kibiki and K. Reither and I. Sanne and Semvua, {H. H.} and A. Tostmann",

year = "2021",

month = apr,

day = "3",

doi = "10.1007/s40262-021-01018-w",

language = "English",

journal = "Clinical Pharmacokinetics",

issn = "0312-5963",

publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Correction to

T2 - A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (Clinical Pharmacokinetics, (2021), 10.1007/s40262-020-00971-2)

AU - the Isoniazid Precision Dosing Group

AU - van Beek, Stijn W.

AU - ter Heine, Rob

AU - Alffenaar, Jan Willem C.

AU - Magis-Escurra, Cecile

AU - Aarnoutse, Rob E.

AU - Svensson, Elin M.

AU - Boeree, M. J.

AU - Burhan, E.

AU - Dawson, R.

AU - Diacon, A. H.

AU - Gillespie, S.

AU - Mtabho, C. M.

AU - Ntingiya, N. E.

AU - Heinrich, N.

AU - Hoefsloot, W.

AU - Hoelscher, M.

AU - Kibiki, G.

AU - Reither, K.

AU - Sanne, I.

AU - Semvua, H. H.

AU - Tostmann, A.

PY - 2021/4/3

Y1 - 2021/4/3

N2 - The original text states that all volume and clearance parameters were allometrically scaled based on total body weight and that allometric scaling based on fat-free mass was not considered as height is not always readily available in TDM practice. During model development, we decided that height can easily be collected and allometric scaling based on fatfree mass should be considered. Allometric scaling based on fat-free mass was significantly better than scaling based on total body weight and was included in the final model. All volume and clearance parameters listed in Table 2 are applicable for a patient with a fat-free mass of 45 kg. This error affects the text in three places:

AB - The original text states that all volume and clearance parameters were allometrically scaled based on total body weight and that allometric scaling based on fat-free mass was not considered as height is not always readily available in TDM practice. During model development, we decided that height can easily be collected and allometric scaling based on fatfree mass should be considered. Allometric scaling based on fat-free mass was significantly better than scaling based on total body weight and was included in the final model. All volume and clearance parameters listed in Table 2 are applicable for a patient with a fat-free mass of 45 kg. This error affects the text in three places:

UR - http://www.scopus.com/inward/record.url?scp=85103620272&partnerID=8YFLogxK

U2 - 10.1007/s40262-021-01018-w

DO - 10.1007/s40262-021-01018-w

M3 - Comment/debate

AN - SCOPUS:85103620272

SN - 0312-5963

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

ER -

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (Clinical Pharmacokinetics, (2021), 10.1007/s40262-020-00971-2)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this